These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37399857)

  • 21. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aldosterone and refractory hypertension.
    Nyirenda MJ; Padfield PL
    Curr Opin Endocrinol Diabetes Obes; 2007 Jun; 14(3):213-8. PubMed ID: 17940442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapy-resistant hypertension--the value of aldosterone antagonists].
    Quack I; Reincke M; Rump LC
    MMW Fortschr Med; 2007 Nov; 149(46):39-40. PubMed ID: 18069192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of mineralocorticoid receptor blockade with direct renin inhibition in angiotensin II-dependent hypertensive mice.
    Hashimoto A; Takeda Y; Karashima S; Kometani M; Aono D; Demura M; Higashitani T; Konishi S; Yoneda T; Takeda Y
    Hypertens Res; 2020 Oct; 43(10):1099-1104. PubMed ID: 32398797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system.
    Viazzi F; Leoncini G; Pontremoli R
    High Blood Press Cardiovasc Prev; 2013 Dec; 20(4):273-82. PubMed ID: 24092648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Salt, the renin-angiotensin-aldosterone system and resistant hypertension.
    Shimosawa T
    Hypertens Res; 2013 Aug; 36(8):657-60. PubMed ID: 23912973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Revising the Roles of Aldosterone in Vascular Physiology and Pathophysiology: From Electocortin to Baxdrostat.
    Feldman RD; Sanjanwala R; Padwal R; Leung AA
    Can J Cardiol; 2023 Dec; 39(12):1808-1815. PubMed ID: 37734710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological treatment of aldosterone excess.
    Deinum J; Riksen NP; Lenders JW
    Pharmacol Ther; 2015 Oct; 154():120-33. PubMed ID: 26213109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypertension in chronic kidney disease-treatment standard 2023.
    Georgianos PI; Agarwal R
    Nephrol Dial Transplant; 2023 Nov; 38(12):2694-2703. PubMed ID: 37355779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.
    Morimoto S; Ichihara A
    Hypertens Res; 2020 Aug; 43(8):744-753. PubMed ID: 32424201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
    Lambers Heerspink HJ
    Contrib Nephrol; 2013; 179():7-14. PubMed ID: 23652444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of Resistant and Refractory Hypertension.
    Acelajado MC; Hughes ZH; Oparil S; Calhoun DA
    Circ Res; 2019 Mar; 124(7):1061-1070. PubMed ID: 30920924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
    Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
    Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aldosterone and arterial hypertension.
    Tomaschitz A; Pilz S; Ritz E; Obermayer-Pietsch B; Pieber TR
    Nat Rev Endocrinol; 2010 Feb; 6(2):83-93. PubMed ID: 20027193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aldosterone antagonism and arterial stiffness.
    Safar ME; Avolio A
    Hypertension; 2004 Feb; 43(2):e3; author reply e3. PubMed ID: 14756124
    [No Abstract]   [Full Text] [Related]  

  • 36. Aldosterone synthase inhibitors in cardiovascular and renal diseases.
    Namsolleck P; Unger T
    Nephrol Dial Transplant; 2014 Feb; 29 Suppl 1():i62-i68. PubMed ID: 24493871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.
    Yugar-Toledo JC; Modolo R; de Faria AP; Moreno H
    Vasc Health Risk Manag; 2017; 13():403-411. PubMed ID: 29081661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mineralocorticoid Receptor Antagonists in Essential and Resistant Hypertension.
    Imprialos KP; Bouloukou S; Kerpiniotis G; Katsimardou A; Patoulias D; Bakogiannis C; Faselis C
    Curr Pharm Des; 2018; 24(46):5500-5507. PubMed ID: 30848188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.
    Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman P; Nyström F; Hägg A; Lind L
    Am J Hypertens; 2002 May; 15(5):389-93. PubMed ID: 12022239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of aldosterone antagonists in the management of resistant hypertension.
    Nishizaka MK; Calhoun DA
    Curr Hypertens Rep; 2005 Oct; 7(5):343-7. PubMed ID: 16157075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.